Rubicon Research Reports Strong Q2 Growth with 56% Jump in Net Profit
Rubicon Research Limited posted strong Q2 FY2026 results with net profit up 56.2% to 539 million rupees and revenue rising 39.2% to 4.12 billion rupees. EBITDA grew 52.9% to 943 million rupees with margin improving to 22.9%. The company's product diversification strategy showed progress with top 5 products now contributing 30% of revenue, down from 34% in Q1. R&D expenses were 11.2% of operating revenue at 475.89 million rupees. Rubicon plans to operationalize its Pithampur plant in mid-2026 to address capacity constraints. The company maintains a strong financial position with 1,514 million rupees in cash and cash equivalents.
*this image is generated using AI for illustrative purposes only.
Rubicon Research Limited, a leading pharmaceutical company, has reported robust financial performance for the second quarter of fiscal year 2026, with significant growth across key metrics.
Financial Highlights
Rubicon Research achieved consolidated net profit of 539.00 million rupees for Q2 FY2026, representing a substantial 56.2% increase from 345.00 million rupees in the same period last year. The company's revenue also saw impressive growth, rising to 4.12 billion rupees compared to 2.96 billion rupees year-over-year, marking a 39.2% increase.
Operational Performance
The company's strong financial results were underpinned by solid operational performance:
- EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew by 52.9% year-on-year to 943.00 million rupees.
- EBITDA margin improved to 22.9%, reflecting enhanced operational efficiency.
- USD revenue reached $47.00 million for Q2 FY26, up by 33% year-on-year and 11.9% quarter-on-quarter.
Product Diversification
Rubicon Research has made significant strides in diversifying its product portfolio:
- Top 5 products contributed 30% of revenue, down from 34% in Q1 FY26.
- Top 10 products accounted for 51% of revenue, compared to 56% in Q1 FY26.
- This diversification provides strong visibility for sustained revenue growth in coming quarters.
Research and Development
The company continues to invest heavily in R&D:
- R&D expenses for Q2 FY26 stood at 475.89 million rupees, representing 11.2% of operating revenue.
- This investment underscores Rubicon's commitment to innovation and future growth.
Manufacturing and Capacity Expansion
Rubicon Research is actively expanding its manufacturing capabilities:
- The company plans to operationalize its Pithampur plant in mid-CY 2026, which is expected to alleviate current capacity constraints.
- Until then, the company may see increased revenue from outsourced manufacturing to meet demand.
Financial Position
As of September 30, 2025, Rubicon Research maintains a strong financial position:
- Cash and cash equivalents stood at 1,514.00 million rupees.
- The company's total assets reached 17,823.35 million rupees.
- Shareholders' funds were reported at 6,474.00 million rupees.
Future Outlook
Rubicon Research's management expressed confidence in the company's growth trajectory, citing:
- A robust pipeline of products under review with the US FDA and under development.
- Focus on specialty products, drug-device combinations, and complex generics.
- Continued investment in R&D and manufacturing capabilities.
The company's strong Q2 performance, coupled with its strategic initiatives, positions Rubicon Research for continued growth in the pharmaceutical sector. Investors and stakeholders will likely watch closely as the company executes its expansion plans and capitalizes on its diversified product portfolio in the coming quarters.
Historical Stock Returns for Rubicon Research
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.87% | -2.39% | -1.62% | +2.36% | +2.36% | +2.36% |
16
